Both PTH-based peptides highlight an important principle in peptide pharmacology: dosing pattern matters as much as the compound itself
Several large-scale cardiovascular outcome trials (including LEADER, SUSTAIN-6, and REWIND) have shown that certain GLP-1 receptor agonists liraglutide, semaglutide, and dulaglutide reduce the risk of major adverse cardiovascular events such as heart attack, stroke, and cardiovascular death in people with established cardiovascular disease or multiple cardiovascular risk factors
Ramakrishna T
See a clinician and check your bloodwork before initiating peptide protocols
Reduo de efeitos adversos de terapias: em pacientes que utilizam inibidores de protease ou passam por processos de hipermetabolismo e caquexia, a l-carnitina pode atuar como coadjuvante, reduzindo sintomas como nuseas, cefalia, indigesto e dores, de acordo com dados de Benson CA, Simone C, Sabba C et al